A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Libri, Vincenzo ^a   Brown, Andrew P ^b   Gambarota, Giulio ^c   Haddad, Jonathan ^d   Shields, Gregory S ^c   Dawes, Helen ^e   Pinato, David J ^a   Hoffman, Ethan ^d   Elliot, Peter J ^d   Vlasuk, George P ^d   Jacobson, Eric ^d   Wilkins, Martin R ^a   Matthews, Paul M ^c,f  

^a Queen Mary University of London and Barts NIHR BRC NHS Trust National Institute for Health and Care Research   (United Kingdom)

^b Imanova Ltd   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e OXFORD BROOKES UNIVERSITY   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CHOLESTEROL; CREATINE PHOSPHATE; ENZYME ACTIVATOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHORUS 31; PLACEBO; SIRTUIN 1; SRT 2104; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AEROBIC CAPACITY; AGED; ARTICLE; BLOOD EXAMINATION; BODY FAT DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ELDERLY CARE; ENZYME ACTIVATION; EXERCISE; FEMALE; HUMAN; MALE; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE PHOSPHORYLATION; PHASE 1 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS;

AGED; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; ENZYME ACTIVATION; EXERCISE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; IMIDAZOLES; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBO EFFECT; SAFETY; SIRTUIN 1; THIAZOLES; TIME FACTORS;

EID: 84871431259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051395     Document Type: Article

References (50)

1. Haigis MC, Sinclair DA, (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253-295.
2. Leibiger IB, Berggren P-O, (2006) Sirt1: a metabolic master switch that modulates lifespan. Nat Med 12: 34-36.
3. Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, et al. (2010) Sirtuin activators: designing molecules to extend life span. Biochim Biophys Acta 1799: 740-749.
4. Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, et al. (2011) SRT1720 improves survival and healthspan of obese mice. Sci Rep (Nature) 1: 1-10.
5. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
6. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, et al. (2008) Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 8: 347-358.
7. Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, et al. (2006) Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 295: 1539-1548.
8. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, et al. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283: 20015-20026.
9. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, et al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776.
10. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, et al. (2006) Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 4.
11. Imai S, Armstrong CM, Kaeberlein M, Guarente L, (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800.
12. Baur JA, (2010) Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev 131: 261-269.
13. Elliott PJ, Walpole S, Morelli L, Lambert PD, Lunsmann W, et al. (2009) Resveratrol/SRT-501. Drugs Fut 34 (4):: 291.
14. Nayagam VM, Wang X, Tan YC, Poulsen A, Goh KC, et al. (2006) SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 11: 959-967.
15. Yang H, Baur JA, Chen A, Miller C, Adams JK, et al. (2007) Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell 6: 35-43.
16. Bemis JE, Vu CB, Xie R, Nunes JJ, Ng PY, et al. (2009) Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg Med Chem Lett 19: 2350-2353.
17. Qi Y DM, Hirsch ML, Cote AM, Lainez EO, Johnson MO, et al. (2010) Activation of Sirtuin1 (SIRT1) by the novel small molecule SRT2104 promotes body weight loss, increases exercise capacity and improves insulin sensitivity in diet-induced obese mice. ADA, 70th Scientific Sessions 390.
18. Suri V DM, Qi Y, Lainez EO, Cote AM, Johnson MO, Gagne DJ, et al. (2011) The Metabolomic Profile of SRT2104, a Selective SIRT1 Activator in High Fat Diet Fed Mice Reveals Significant Improvements in Metabolic Function in Liver, Heart and Skeletal Muscle. ADA, 71th Scientific Sessions 1706.
19. Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, et al. (2012) Pharmacokinetics and Tolerability of SRT2104, a First-In-Class Small Molecule Activator of SIRT1, after Single and Repeated Oral Administration in Man. Br J Clin Pharmacol doi:10.1111/j.1365-2125.2012.04340.x.
20. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group (1998) Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 8: 371-375.
21. He Y-L, Wang Y, Bullock JM, Deacon CF, Holst JJ, et al. (2007) Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 47: 633-641.
22. Matthews PM, Allaire C, Shoubridge EA, Karpati G, Carpenter S, et al. (1991) In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 41: 114-120.
23. Larson-Meyer DE, Newcomer BR, Hunter GR, Hetherington HP, Weinsier RL, (2000) 31P MRS measurement of mitochondrial function in skeletal muscle: reliability, force-level sensitivity and relation to whole body maximal oxygen uptake. NMR Biomed 13: 14-27.
24. Schocke MFH, Esterhammer R, Kammerlander C, Rass A, Kremser C, et al. (2004) High-energy phosphate metabolism during incremental calf exercise in humans measured by 31 phosphorus magnetic resonance spectroscopy (31P MRS). Magn Reson Imaging 22: 109-115.
25. Kemp GJ, Radda GK, (1994) Quantitative interpretation of bioenergetic data from 31P and 1H magnetic resonance spectroscopic studies of skeletal muscle: an analytical review. Magn Reson Q 10: 43-63.
26. Larson-Meyer DE, Newcomer BR, Hunter GR, Joanisse DR, Weinsier RL, et al. (2001) Relation between in vivo and in vitro measurements of skeletal muscle oxidative metabolism. Muscle Nerve 24: 1665-1676.
27. Hume R, (1966) Prediction of lean body mass from height and weight. J Clin Pathol 19: 389-391.
28. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, et al. (2001) Java-based graphical user interface for the MRUI quantitation package. MAGMA 12: 141-152.
29. Vanderthommen M, Duteil S, Wary C, Raynaud JS, Leroy-Willig A, et al. (2003) A comparison of voluntary and electrically induced contractions by interleaved 1H- and 31P-NMRS in humans. J Appl Physiol 94: 1012-1024.
30. Rofsky NM, Lee VS, Laub G, Pollack MA, Krinsky GA, et al. (1999) Abdominal MR imaging with a volumetric interpolated breath-hold examination. Radiology 212: 876-884.
31. Thomas EL, Saeed N, Hajnal JV, Brynes A, Goldstone AP, et al. (1998) Magnetic resonance imaging of total body fat. J Appl Physiol 85: 1778-1785.
32. Medicine ACoS (2009) ACSM's Guidelines for exercise testing and prescription. Philadelphia, PA: Lippincott, Williams and Wilkins.
33. Rostami-Hodjegan A, Tucker GT, (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6: 140-148.
34. Zern TL, West KL, Fernandez ML, (2003) Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J Nutr 133: 2268-2272.
35. Do G-M, Kwon E-Y, Kim H-J, Jeon S-M, Ha T-Y, et al. (2008) Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 374: 55-59.
36. Li X, Zhang S, Blander G, Tse JG, Krieger M, et al. (2007) SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 28: 91-9106.
37. Jacobson EL, Kim H, Kim M, Jacobson MK, (2012) Niacin: vitamin and antidyslipidemic drug. Subcell Biochem 56: 37-47.
38. Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, et al. (2010) Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab 95: 2727-35.
39. Ponugoti B, Kim D-H, Xiao Z, Smith Z, Miao J, et al. (2010) SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 285: 33959-33970.
40. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, et al. (1996) Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39: 298-305.
41. Utzschneider KM, Prigeon RL, Tong J, Gerchman F, Carr DB, et al. (2007) Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. Diabetologia 50: 2516-2525.
42. Gurd BJ, Yoshida Y, McFarlan JT, Holloway GP, Moyes CD, et al. (2011) Nuclear SIRT1 activity, but not protein content, regulates mitochondrial biogenesis in rat and human skeletal muscle. Am J Physiol Regul Integr Comp Physiol 301: 67-75.
43. Menzies KJ, Hood DA, (2012) The role of SirT1 in muscle mitochondrial turnover. Mitochondrion 12: 5-13.
44. Tomlin DL, Wenger HA, (2001) The relationship between aerobic fitness and recovery from high intensity intermittent exercise. Sports Med 31: 1-11.
45. Bassett DR, Howley ET, (2000) Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med Sci Sports Exerc 32: 70-84.
46. Dandurand RJ, Matthews PM, Arnold DL, Eidelman DH, (1995) Mitochondrial disease. Pulmonary function, exercise performance, and blood lactate levels. Chest 108: 182-9.
47. Layec G, Haseler LJ, Richardson RS, (2012) Reduced muscle oxidative capacity is independent of O2 availability in elderly people. Age doi:10.1007/s11357-012-9442-6.
48. Thomas EL, Makwana A, Newbould R, Rao AW, Gambarota G, et al. (2011) Pragmatic study of orlistat 60 mg on abdominal obesity. Eur J Clin Nutr 65: 1256-1262.
49. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, et al. (2004) Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27: 33-40.
50. Berggren JR, Boyle KE, Chapman WH, Houmard JA, (2008) Skeletal muscle lipid oxidation and obesity: influence of weight loss and exercise. Am J Physiol Endocrinol Metab 294: 726-32.